Lille ; Cambridge ; Zurich ; September 26, 2023 - GENFIT , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the.
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); September 26, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients
Led by the director of Virginia Commonwealth University’s Stravitz-Sanyal Institute of Liver Disease and Metabolic Health, a consortium studying noninvasive tests for liver disease has demonstrated the effectiveness of five noninvasive tests, a significant milestone on the path to regulatory approval.
Noninvasive biomarker tests could be alternatives to painful liver biopsies medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
New biomarker tests identified NASH and related conditions at least as well as common lab tests, paving the way for blood-based alternatives to liver biopsy for clinical care and therapeutic trials.